Quick Answer
Allogene Therapeutics, Inc. reported Net Income Loss of -$190.89 million for the year ending 2025.
- Allogene Therapeutics, Inc. showed an increase of +25.9% in Net Income Loss from 2024 to 2025.
- This data is from Allogene Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 12, 2026.
- XBRL data for this metric is available from 2017 to 2025 (9 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 9 years of available data (2017 to 2025), Allogene Therapeutics, Inc.'s Net Income Loss has declined by 9,544,200.0%.
- Historical annual values: Fiscal year 2025: -$190.89 million | Fiscal year 2024: -$257.59 million | Fiscal year 2023: -$327.27 million | Fiscal year 2022: -$340.41 million | Fiscal year 2021: -$182.05 million | Fiscal year 2020: -$250.22 million | Fiscal year 2019: -$184.59 million | Fiscal year 2018: -$211.51 million | Fiscal year 2017: -$2.0 thousand.
- Data sourced from SEC EDGAR public filings as of June 20, 2026.
Last verified: